A Phase 1 interventional study of Immunotherapeutic GSK2302025A, different formulations in Melanoma, sponsored by GlaxoSmithKline. Completed at 37 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-20.
Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment
The purpose of this clinical study is to examine the safety, immunogenicity and clinical activity of the immunotherapeutic product GSK2302025A (also referred to as recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic [ASCI]) administered as a first line treatment in patients with unresectable and progressive metastatic cutaneous melanoma.
In this study, patients were to receive a maximum of 24 doses of recMAGE-A3 + AS15 according to four cycles over a period of four years. An active follow-phase (up to five years after registration into the study) was planned for all patients.
This protocol summary has been impacted by protocol amendment 3, so there will no longer be an active follow-up of patients after discontinuation or completion of the study treatment. The study will end approximately 30 days after the last dose will be administered.
In addition, no more biological samples will be collected for protocol research purposes. For each biological sample already collected in the scope of this study and not tested yet, testing will not be performed by default, except if a scientific rationale remains relevant.
Sampling for safety monitoring as per protocol will continue.
3,006 studies on the registry are indexed under Melanoma; 520 are open to participants now.
This study's enrollment of 107 is above the median of 38 across 2,351 interventional studies indexed under Melanoma.
Browse Melanoma studies →GlaxoSmithKline is the lead sponsor of 3,562 studies on the registry; 117 are open to participants now.
Of its 258 completed or terminated interventional studies of FDA-regulated products, 232 (90%) have results posted.
Counted across the registry records on this site, refreshed daily.
Male or female patient with histologically proven cutaneous melanoma. Phase I segment: All melanoma patients with stage IV M1b and stage IV M1c including completely resected stage IV patients but with the exception of stage IV M1c disease with serum lactate dehydrogenase > 1.5 x Upper Limit of Normal or with involvement of the Central Nervous System.
Phase II segment: All melanoma patients with measurable, unresectable stage III melanoma including in-transit metastasis (with (N3) or without (N2c) nodal metastasis) and stage IV M1a melanoma. The patient should have documented progressive disease within 12 weeks of registration into the trial. Patients with resected stage IV and with stage IV M1b or M1c disease cannot be included.
Female patients of childbearing potential may be enrolled in the study, if the patient:
Exclusion Criteria:
Male or female patients with histologically proven cutaneous melanoma received the investigational Low-Dose (LD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
Biological: Immunotherapeutic GSK2302025A, different formulations
Male or female patients with histologically proven cutaneous melanoma received the investigational Middle-Dose (MD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
Biological: Immunotherapeutic GSK2302025A, different formulations
Male or female patients with histologically proven cutaneous melanoma received the investigational High-Dose (HD) adjuvanted GSK2302025A immunotherapeutic vaccine, intramuscularly into the deltoid or lateral region of the thigh, with alternation on right or left side at each succeeding injection. Subjects received a total of 24 administrations in 4 cycles: 6 administrations given at 2 weeks intervals in cycle 1, 6 administrations given at 3 weeks intervals in cycle 2, 4 administrations given at 6 weeks intervals in cycle 3 and 4 administrations given at 3 months interval in cycle 4.
Biological: Immunotherapeutic GSK2302025A, different formulations
In Phase 2 of the study subjects received the optimal investigational dose-level identified in Phase 1. Patients received a treatment consisting of 24 injections of the experimental GSK2302025A immunotherapeutic.
Biological: Immunotherapeutic GSK2302025A, different formulations
Intramuscular administration
Also known as: PRAME ASCI
Number of Patients With Dose-limiting Toxicity (Phase I)
The dose-limiting toxicities (DLT) were defined as follows: •An Antigen-Specific Cancer Immunotherapeutic (ASCI) related or possibly ASCI related grade 3 or higher toxicity. Grade 3 myalgia, arthralgia, headache, fever, rigors/chills and fatigue (including lethargy, malaise and asthenia) persisting for 48 hours despite therapy. •An ASCI related or possibly ASCI related grade 2 or higher allergic reaction occurring within 24 hours following the ASCI administration. •An ASCI related or possibly ASCI related decrease in renal function, with a creatinine clearance lower than (\<) 40 milliliters per minute (mL/min). •An ASCI-related or possibly ASCI-related symptomatic and confirmed adrenal insufficiency. The grading used was defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: Grade 3 DLT = severe DLT. Related = DLT considered by investigator as possibly related to product administration.
Time frame: During the study treatment (up to Year 4), for all patients
Percentage of Patients With Anti-PReferentially Expressed Antigen of MElanoma (Anti-PRAME) Humoral Immune Response (Phase I)
A seronegative/seropositive patient for anti-PRAME antibodies was a patient with antibody concentration lower (\<)/ higher than or equal to (≥) cut-off level. Humoral immune response was defined as a) if baseline concentration \< cut-off level: post treatment concentration ≥ cut-off level, or b) if baseline concentration ≥ cut-off level: post treatment concentration at least twice the baseline value. Cut-off values for seropositivity (by enzyme-linked immunosorbent assay \[ELISA\]) were 12 ELISA Units per milliliter (EL.U/mL).
Time frame: After the administration of dose 4, at Week 8
Number of Patients With Best Overall Response to Study Treatment (Phase II)
The best overall response is the best response recorded from the start of the treatment until disease progression (taking as reference for progressive disease the smallest measurements recorded since the treatment started). In general the patient's best response assignment depended on the achievement of both measurement and confirmation criteria. The best overall response includes the complete response (CR) defined as disappearance of all targeted/non-targeted lesions and partial response (PR) defined as at least 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD and persistence of one or more non-targeted lesion(s).
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Any Unsolicited Adverse Events (AEs), by Maximum Grading
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. The grading to be used by the investigators for the assessment of the severity of adverse events (AEs) was defined as the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE). Adverse Events were coded to the preferred term (PT) level by means of the Medical Dictionary for Regulatory Activities (MedDRA).
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Serious Adverse Events (SAEs), by Maximum Grading
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. The grading to be used by the investigators for the assessment of the severity of adverse events (AEs) was defined as the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE). SAEs were coded to the preferred term (PT) level by means of the Medical Dictionary for Regulatory Activities (MedDRA).
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Laboratory Abnormalities Versus Baseline, by Maximum Grading
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Unknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[APTTP\] grading versus baseline parameter grading.
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Laboratory Abnormal Results Versus Baseline, by Maximum Grading
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[ALT/I\] and \[APH/I\] grading versus baseline parameter grading.
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Hematological and Biochemical Abnormalities Versus Baseline, by Maximum Grading
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[AN\], \[AST/I\] and \[CRE/I\] grading versus baseline parameter grading.
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Laboratory Hematological and Biochemical Abnormalities Versus Baseline, by Maximum Grading
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[CRE/I\] and \[GGT/I\] grading versus baseline parameter grading.
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Lab Hematological and Biochemical Abnormalities Versus Baseline, by Maximum Grading
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[Hgb/I\] and \[HYP\] grading versus baseline parameter grading.
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Abnormal Hematological and Biochemical Results Versus Baseline, by Maximum Grading
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[LYMC/D\] and \[LYMC/I\] grading versus baseline parameter grading.
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Number of Patients With Abnormal Hematological and Biochemical Laboratory Results Versus Baseline, by Maximum Grading
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[NEUC/D\], \[PLA/D\] and \[WBC/D\] grading versus baseline parameter grading.
Time frame: During the entire study period - up to Year 4 + 1 month post last study treatment administration
Percentage of Patients With Anti-PRAME Cellular (T-cell) Response (Phase I)
Cellular response was defined as: Geometric Mean Response (GMR) above the 2.68 cut-off value and at least a four-fold increase of PRAME- specific Cluster of Differentiation (CD) 4/8 T-cells. Considering that 2 studies failed to demonstrate clinical efficacy of recombinant protein based cancer vaccines, GSK decided in 2014 to stop the development and to stop recruitment in all the ongoing clinical studies. The decision was made to end the study (i.e., stopping patient enrollment, follow-ups, sample collection and analysis of samples for research purposes). Patients still on treatment at the time of the protocol amendment were offered to continue the administration of the study treatment until the last dose or until recurrence, whichever came first, or until the patient or the investigator decided to stop the study treatment. No further active protocol visit/contact was performed except for the concluding visit at Week 199, 30 days after the last treatment administration.
Time frame: Up to Data Lock Point at Week 8
Number of Patients With Anti-PRAME Humoral Immune Response (Phase I & II)
A seropositive patient was a patient whose anti-PRAME antibody concentration was greater than or equal to (≥) the assay cut-off value of 12 ELISA units per milliliter (EL.U/mL). A seronegative patient was defined as a patient whose pre-treatment antibody concentration was below (\<) the cut-off value. An anti-PRAME antibody responder was defined as: For a seronegative patient: a post-treatment antibody concentration ≥ the cut-off value; For a seropositive patient: a post-treatment antibody concentration ≥ twice the pre-treatment antibody concentration.
Time frame: At Weeks 0, 4, 8, 10, 12, 29, 51, 75, 99, 123, 147 and conclusion visit at 30 days post last treatment administration (Week 199) for each patient
Number of Patients With Stable Disease (SD), Progressive Disease (PD), Mixed Response (MR) (Phase I & II)
Tumor response was assessed by the Response Evaluation Criteria In Solid Tumors (RECIST), where stable disease for target lesions refers to neither enough shrinkage to qualify for complete response nor sufficient increase to qualify for progressive disease taking as references the smallest sum longest diameter (LD) since the treatment started. For non-targeted lesions it refers to persistence of one or more non-target lesions. Progressive disease is related to a clear increase of diameters of lesions taking as references the smallest diameters recorded since the treatment started OR the appearance of one or more new lesions OR both of these.
Time frame: At 30 days after the last treatment administration for each patient (Week 199)
Number of Patients With Best Overall Response, Including Mixed Response (MxR) and Slow Progressive Disease (SPD) Criteria (Phase I & II)
Tumor response was assessed by the RECIST criteria, where SD for target lesions refers to neither enough shrinkage to qualify for CR nor sufficient increase to qualify for PD taking as references the smallest sum longest diameter (LD) since the treatment started. For non-targeted lesions it refers to persistence of one or more nom-target lesions. Progressive disease is related to a clear increase of diameters of lesions taking as references the smallest diameters recorded since the treatment started OR the appearance of one or more new lesions OR both of these. Mixed response is defined as at least 30% decrease in the LD occurring in at least one target lesion recorded and measured at baseline. Such response occurring in otherwise SD or PD status of the LD of target lesions were classified as "SD with target lesion regression" or "PD with target lesion regression", respectively. New lesion(s) in otherwise PR status of the LD of target lesions were "PR with new lesion".
Time frame: At 30 days after the last treatment administration for each patient (Week 199)
Anti-Protein D Humoral Response (Phase I & II)
Analysis of immunogenicity for anti-PD antibodies was not performed, following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-PD antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.
Time frame: At Week 0, 4, 8, 12, 29, 51, 75, 99, 123, 147, 30 days after the last treatment administration for each patient (Week 199), with follow-up, 3, 6, 9 and 12 months after concluding visit
Anti-Cytosine Phosphate Guanosine Oligodeoxynucleotide (CpG) Humoral Response (Phase I & II)
Analysis of immunogenicity for anti-CpG antibodies was not performed, following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-CpG antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.
Time frame: At Week 0, 4, 8, 12, 29, 51, 75, 99, 123, 147, 30 days after the last treatment administration for each patient (Week 199), with follow-up, 3, 6, 9 and 12 months after concluding visit
Time to Treatment Failure, Progression Free Survival and Overall Survival (Phase I & II)
Time to treatment failure (TTF) was defined as the time from first administration of study product until the date of the last administration of the product, irrespective of the reason for study treatment discontinuation. Progression-free survival (PFS) was defined as the time from first adminsitration of study product until the date of either disease progression or death (for whatever reason), whichever comes first. Overall survival (OS) was defined as the time from first administration of study product until death.
Time frame: Up to concluding visit, at Week 199
Duration of Response for Patients With CR, PR and SD or SD/PR Status (Phase II)
This analysis was not performed following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-CpG/anti-PD antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.
Time frame: Up to concluding visit, at Week 199
| Milestone | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| Started | 20 | 24 | 22 | 40 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 20 | 24 | 22 | 40 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 5 |
| Withdrew: Death | 10 | 13 | 18 | 18 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 |
| Withdrew: Other | 8 | 10 | 2 | 14 |
| Withdrew: Sponsor study termination | 0 | 0 | 0 | 2 |
| Withdrew: Recurrence / progressive disease | 0 | 0 | 1 | 0 |
The dose-limiting toxicities (DLT) were defined as follows: •An Antigen-Specific Cancer Immunotherapeutic (ASCI) related or possibly ASCI related grade 3 or higher toxicity. Grade 3 myalgia, arthralgia, headache, fever, rigors/chills and fatigue (including lethargy, malaise and asthenia) persisting for 48 hours despite therapy. •An ASCI related or possibly ASCI related grade 2 or higher allergic reaction occurring within 24 hours following the ASCI administration. •An ASCI related or possibly ASCI related decrease in renal function, with a creatinine clearance lower than (\<) 40 milliliters per minute (mL/min). •An ASCI-related or possibly ASCI-related symptomatic and confirmed adrenal insufficiency. The grading used was defined according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0: Grade 3 DLT = severe DLT. Related = DLT considered by investigator as possibly related to product administration.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 |
|---|---|---|---|
| Patients with DLT | 0 | 1 | 1 |
| Patients with related DLT | 0 | 1 | 1 |
| Patients with severe DLT | 0 | 1 | 1 |
| Brain oedema | 0 | 1 | 0 |
| Microalbuminuria | 0 | 0 | 1 |
| Proteinuria | 0 | 0 | 1 |
A seronegative/seropositive patient for anti-PRAME antibodies was a patient with antibody concentration lower (\<)/ higher than or equal to (≥) cut-off level. Humoral immune response was defined as a) if baseline concentration \< cut-off level: post treatment concentration ≥ cut-off level, or b) if baseline concentration ≥ cut-off level: post treatment concentration at least twice the baseline value. Cut-off values for seropositivity (by enzyme-linked immunosorbent assay \[ELISA\]) were 12 ELISA Units per milliliter (EL.U/mL).
| Percentage of patients | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 |
|---|---|---|---|
| Percentage of Patients With Anti-PReferentially Expressed Antigen of MElanoma (Anti-PRAME) Humoral Immune Response (Phase I) | 100 (75.3 to 100) | 100 (75.3 to 100) | 100 (80.5 to 100) |
The best overall response is the best response recorded from the start of the treatment until disease progression (taking as reference for progressive disease the smallest measurements recorded since the treatment started). In general the patient's best response assignment depended on the achievement of both measurement and confirmation criteria. The best overall response includes the complete response (CR) defined as disappearance of all targeted/non-targeted lesions and partial response (PR) defined as at least 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD and persistence of one or more non-targeted lesion(s).
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| Patients with CR | 0 | 0 | 0 | 0 |
| Patients with PR | 0 | 0 | 0 | 4 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. The grading to be used by the investigators for the assessment of the severity of adverse events (AEs) was defined as the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE). Adverse Events were coded to the preferred term (PT) level by means of the Medical Dictionary for Regulatory Activities (MedDRA).
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| Grade 1 | 9 | 9 | 8 | 12 |
| Grade 2 | 6 | 6 | 10 | 15 |
| Grade 3 | 4 | 5 | 3 | 7 |
| Grade 4 | 1 | 1 | 0 | 3 |
| Grade 5 | 0 | 0 | 0 | 2 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity. The grading to be used by the investigators for the assessment of the severity of adverse events (AEs) was defined as the Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe or medically significant; Grade 4 = life-threatening; Grade 5 = death related to AE). SAEs were coded to the preferred term (PT) level by means of the Medical Dictionary for Regulatory Activities (MedDRA).
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| Grade 1 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 1 | 0 |
| Grade 3 | 2 | 2 | 1 | 0 |
| Grade 4 | 1 | 1 | 0 | 3 |
| Grade 5 | 0 | 0 | 0 | 2 |
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Unknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[APTTP\] grading versus baseline parameter grading.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| [APTTP], G0-GUnknown | 0 | 0 | 0 | 0 |
| [APTTP], G1-GUnknown | 0 | 0 | 0 | 0 |
| [APTTP], G2-GUnknown | 0 | 0 | 0 | 0 |
| [APTTP], G3-GUnknown | 0 | 0 | 0 | 1 |
| [APTTP], G4-GUnknown | 0 | 0 | 0 | 0 |
| [APTTP], GUknown-GUnknown | 2 | 0 | 1 | 0 |
| [APTTP], G0-G0 | 13 | 16 | 18 | 33 |
| [APTTP], G1-G0 | 2 | 3 | 1 | 3 |
| [APTTP], G2-G0 | 0 | 0 | 1 | 0 |
| [APTTP], G3-G0 | 0 | 1 | 0 | 1 |
| [APTTP], G4-G0 | 0 | 0 | 0 | 0 |
| [APTTP], GUnknown-G0 | 2 | 0 | 1 | 0 |
| [APTTP], G0-G1 | 0 | 1 | 0 | 1 |
| [APTTP], G1-G1 | 0 | 2 | 0 | 0 |
| [APTTP], G2-G1 | 0 | 0 | 0 | 1 |
| [APTTP], G3-G1 | 0 | 0 | 0 | 0 |
| [APTTP], G4-G1 | 0 | 0 | 0 | 0 |
| [APTTP], GUnknown-G1 | 0 | 1 | 0 | 0 |
| [APTTP], G0-G2 | 0 | 0 | 0 | 0 |
| [APTTP], G1-G2 | 0 | 0 | 0 | 0 |
| [APTTP], G2-G2 | 1 | 0 | 0 | 0 |
| [APTTP], G3-G2 | 0 | 0 | 0 | 0 |
| [APTTP], G4-G2 | 0 | 0 | 0 | 0 |
| [APTTP], GUknown-G2 | 0 | 0 | 0 | 0 |
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[ALT/I\] and \[APH/I\] grading versus baseline parameter grading.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| [ALT/I], G0-G0 | 11 | 18 | 16 | 34 |
| [ALT/I], G1-G0 | 4 | 4 | 5 | 1 |
| [ALT/I], G2-G0 | 0 | 0 | 0 | 1 |
| [ALT/I], G3-G0 | 0 | 0 | 0 | 0 |
| [ALT/I], G4-G0 | 0 | 0 | 0 | 0 |
| [ALT/I], GUknown-G0 | 2 | 0 | 1 | 0 |
| [ALT/I], G0-G1 | 0 | 2 | 0 | 1 |
| [ALT/I], G1-G1 | 3 | 0 | 0 | 3 |
| [ALT/I], G2-G1 | 0 | 0 | 0 | 0 |
| [ALT/I], G3-G1 | 0 | 0 | 0 | 0 |
| [ALT/I], G4-G1 | 0 | 0 | 0 | 0 |
| [ALT/I], GUknown-G1 | 0 | 0 | 0 | 0 |
| [APH/I], G0-G0 | 16 | 20 | 15 | 33 |
| [APH/I], G1-G0 | 1 | 3 | 5 | 5 |
| [APH/I], G2-G0 | 0 | 0 | 1 | 1 |
| [APH/I], G3-G0 | 0 | 0 | 0 | 0 |
| [APH/I], G4-G0 | 0 | 0 | 0 | 0 |
| [APH/I], GUknown-G0 | 2 | 0 | 1 | 0 |
| [APH/I], G0-G1 | 0 | 0 | 0 | 0 |
| [APH/I], G1-G1 | 0 | 0 | 0 | 1 |
| [APH/I], G2-G1 | 0 | 1 | 0 | 0 |
| [APH/I], G3-G1 | 0 | 0 | 0 | 0 |
| [APH/I], G4-G1 | 0 | 0 | 0 | 0 |
| [APH/I], GUknokwn-G1 | 0 | 0 | 0 | 0 |
| [APH/I], G0-G2 | 0 | 0 | 0 | 0 |
| [APH/I], G1-G2 | 0 | 0 | 0 | 0 |
| [APH/I], G2-G2 | 0 | 0 | 0 | 0 |
| [APH/I], G3-G2 | 1 | 0 | 0 | 0 |
| [APH/I], G4-G2 | 0 | 0 | 0 | 0 |
| [APH/I], GUknown-G2 | 0 | 0 | 0 | 0 |
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[AN\], \[AST/I\] and \[CRE/I\] grading versus baseline parameter grading.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| [AN], G0-G0 | 12 | 10 | 10 | 21 |
| [AN], G1-G0 | 1 | 6 | 5 | 12 |
| [AN], G2-G0 | 0 | 0 | 1 | 3 |
| [AN], G3-G0 | 1 | 0 | 0 | 0 |
| [AN], G4-G0 | 0 | 0 | 0 | 0 |
| [AN], GUknown-G0 | 1 | 0 | 1 | 0 |
| [AN], G0-G1 | 2 | 1 | 0 | 0 |
| [AN], G1-G1 | 2 | 5 | 5 | 4 |
| [AN], G2-G1 | 0 | 1 | 0 | 0 |
| [AN], G3-G1 | 0 | 1 | 0 | 0 |
| [AN], G4-G1 | 0 | 0 | 0 | 0 |
| [AN], GUnknown-G1 | 1 | 0 | 0 | 0 |
| [AST/I], G0-G0 | 13 | 18 | 17 | 36 |
| [AST/I], G1-G0 | 3 | 6 | 4 | 2 |
| [AST/I], G2-G0 | 0 | 0 | 0 | 0 |
| [AST/I], G3-G0 | 0 | 0 | 0 | 0 |
| [AST/I], G4-G0 | 0 | 0 | 0 | 0 |
| [AST/I], GUnknown-G0 | 1 | 0 | 1 | 0 |
| [AST/I], G0-G1 | 1 | 0 | 0 | 0 |
| [AST/I], G1-G1 | 1 | 0 | 0 | 2 |
| [AST/I], G2-G1 | 0 | 0 | 0 | 0 |
| [AST/I], G3-G1 | 0 | 0 | 0 | 0 |
| [AST/I], G4-G1 | 0 | 0 | 0 | 0 |
| [AST/I], GUnknown-G1 | 1 | 0 | 0 | 0 |
| [BB/I], G0-G0 | 16 | 21 | 19 | 38 |
| [BB/I], G1-G0 | 1 | 2 | 1 | 0 |
| [BB/I], G2-G0 | 1 | 0 | 0 | 0 |
| [BB/I], G3-G0 | 0 | 0 | 0 | 0 |
| [BB/I], G4-G0 | 0 | 0 | 0 | 0 |
| [BB/I], GUnknown-G0 | 2 | 0 | 1 | 0 |
| [BB/I], G0-G1 | 0 | 0 | 0 | 0 |
| [BB/I], G1-G1 | 0 | 1 | 1 | 1 |
| [BB/I], G2-G1 | 0 | 0 | 0 | 1 |
| [BB/I], G3-G1 | 0 | 0 | 0 | 0 |
| [BB/I], G4-G1 | 0 | 0 | 0 | 0 |
| [BB/I], GUnknown-G1 | 0 | 0 | 0 | 0 |
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[CRE/I\] and \[GGT/I\] grading versus baseline parameter grading.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| [CRE/I], G0-G0 | 20 | 22 | 20 | 33 |
| [CRE/I], G1-G0 | 0 | 0 | 1 | 6 |
| [CRE/I], G2-G0 | 0 | 0 | 0 | 0 |
| [CRE/I], G3-G0 | 0 | 0 | 0 | 0 |
| [CRE/I], G4-G0 | 0 | 0 | 0 | 0 |
| [CRE/I], GUnknown-G0 | 0 | 0 | 0 | 0 |
| [CRE/I], G0-G1 | 0 | 0 | 0 | 0 |
| [CRE/I], G1-G1 | 0 | 1 | 1 | 0 |
| [CRE/I], G2-G1 | 0 | 0 | 0 | 0 |
| [CRE/I], G3-G1 | 0 | 0 | 0 | 0 |
| [CRE/I], G4-G1 | 0 | 0 | 0 | 0 |
| [CRE/I], GUnknown-G1 | 0 | 0 | 0 | 0 |
| [CRE/I], G0-G2 | 0 | 0 | 0 | 0 |
| [CRE/I], G1-G2 | 0 | 0 | 0 | 0 |
| [CRE/I], G2-G2 | 0 | 1 | 0 | 1 |
| [CRE/I], G3-G2 | 0 | 0 | 0 | 0 |
| [CRE/I], G4-G2 | 0 | 0 | 0 | 0 |
| [CRE/I], GUknown-G2 | 0 | 0 | 0 | 0 |
| [GGT/I], G0-G0 | 10 | 17 | 14 | 30 |
| [GGT/I], G1-G0 | 1 | 1 | 1 | 4 |
| [GGT/I], G2-G0 | 2 | 2 | 1 | 0 |
| [GGT/I], G3-G0 | 0 | 0 | 0 | 0 |
| [GGT/I], G4-G0 | 0 | 0 | 0 | 1 |
| [GGT/I], GUnknown-G0 | 1 | 0 | 1 | 0 |
| [GGT/I], G0-G1 | 2 | 1 | 1 | 1 |
| [GGT/I], G1-G1 | 0 | 1 | 1 | 3 |
| [GGT/I], G2-G1 | 1 | 1 | 0 | 0 |
| [GGT/I], G3-G1 | 0 | 0 | 1 | 0 |
| [GGT/I], G4-G1 | 0 | 0 | 0 | 0 |
| [GGT/I], GUnknown-G1 | 1 | 0 | 0 | 0 |
| [GGT/I], G0-G2 | 0 | 0 | 0 | 0 |
| [GGT/I], G1-G2 | 0 | 1 | 0 | 0 |
| [GGT/I], G2-G2 | 0 | 0 | 0 | 0 |
| [GGT/I], G3-G2 | 1 | 0 | 2 | 0 |
| [GGT/I], G4-G2 | 0 | 0 | 0 | 0 |
| [GGT/I], GUnknown-G2 | 1 | 0 | 0 | 0 |
| [GGT/I], G0-G3 | 0 | 0 | 0 | 0 |
| [GGT/I], G1-G3 | 0 | 0 | 0 | 0 |
| [GGT/I], G2-G3 | 0 | 0 | 0 | 0 |
| [GGT/I], G3-G3 | 0 | 0 | 0 | 1 |
| [GGT/I], G4-G3 | 0 | 0 | 0 | 0 |
| [GGT/I], GUnknown-G3 | 0 | 0 | 0 | 0 |
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[Hgb/I\] and \[HYP\] grading versus baseline parameter grading.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| [Hgb/I], G0-G0 | 16 | 24 | 21 | 37 |
| [Hgb/I], G1-G0 | 0 | 0 | 0 | 2 |
| [Hgb/I], G2-G0 | 0 | 0 | 0 | 0 |
| [Hgb/I], G3-G0 | 0 | 0 | 0 | 0 |
| [Hgb/I], G4-G0 | 0 | 0 | 0 | 0 |
| [Hgb/I], GUnknown-G0 | 2 | 0 | 1 | 0 |
| [Hgb/I], G0-G1 | 0 | 0 | 0 | 0 |
| [Hgb/I], G1-G1 | 1 | 0 | 0 | 0 |
| [Hgb/I], G2-G1 | 0 | 0 | 0 | 1 |
| [Hgb/I], G3-G1 | 0 | 0 | 0 | 0 |
| [Hgb/I], G4-G1 | 0 | 0 | 0 | 0 |
| [Hgb/I], GUnknown-G1 | 0 | 0 | 0 | 0 |
| [Hgb/I], G0-G2 | 0 | 0 | 0 | 0 |
| [Hgb/I], G1-G2 | 1 | 0 | 0 | 0 |
| [Hgb/I], G2-G2 | 0 | 0 | 0 | 0 |
| [Hgb/I], G3-G2 | 0 | 0 | 0 | 0 |
| [Hgb/I], G4-G2 | 0 | 0 | 0 | 0 |
| [Hgb/I], GUnknown-G2 | 0 | 0 | 0 | 0 |
| [HYP], G0-G0 | 13 | 17 | 18 | 30 |
| [HYP], G1-G0 | 2 | 5 | 2 | 5 |
| [HYP], G2-G0 | 0 | 1 | 0 | 1 |
| [HYP], G3-G0 | 0 | 0 | 0 | 0 |
| [HYP], G4-G0 | 0 | 0 | 0 | 0 |
| [HYP], GUnknown-G0 | 3 | 0 | 2 | 0 |
| [HYP], G0-G1 | 0 | 0 | 0 | 0 |
| [HYP], G1-G1 | 1 | 1 | 0 | 3 |
| [HYP], G2-G1 | 1 | 0 | 0 | 0 |
| [HYP], G3-G1 | 0 | 0 | 0 | 0 |
| [HYP], G4-G1 | 0 | 0 | 0 | 0 |
| [HYP], GUnknown-G1 | 0 | 0 | 0 | 0 |
| [HYP], G0-G3 | 0 | 0 | 0 | 1 |
| [HYP], G1-G3 | 0 | 0 | 0 | 0 |
| [HYP], G2-G3 | 0 | 0 | 0 | 0 |
| [HYP], G3-G3 | 0 | 0 | 0 | 0 |
| [HYP], G4-G3 | 0 | 0 | 0 | 0 |
| [HYP], GUnknown-G3 | 0 | 0 | 0 | 0 |
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[ NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grade (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[LYMC/D\] and \[LYMC/I\] grading versus baseline parameter grading.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| [LYMC/D], G0-G0 | 10 | 14 | 14 | 28 |
| [LYMC/D], G1-G0 | 3 | 4 | 3 | 4 |
| [LYMC/D], G2-G0 | 1 | 1 | 0 | 0 |
| [LYMC/D], G3-G0 | 0 | 0 | 0 | 0 |
| [LYMC/D], G4-G0 | 0 | 0 | 0 | 0 |
| [LYMC/D], GUnknown-G0 | 0 | 0 | 1 | 0 |
| [LYMC/D], G0-G1 | 0 | 1 | 1 | 2 |
| [LYMC/D], G1-G1 | 3 | 3 | 2 | 5 |
| [LYMC/D], G2-G1 | 1 | 0 | 0 | 0 |
| [LYMC/D], G3-G1 | 0 | 0 | 0 | 0 |
| [LYMC/D], G4-G1 | 0 | 0 | 0 | 0 |
| [LYMC/D], GUnknown-G1 | 1 | 1 | 0 | 0 |
| [LYMC/D], G0-G2 | 0 | 0 | 0 | 0 |
| [LYMC/D], G1-G2 | 0 | 0 | 1 | 0 |
| [LYMC/D], G2-G2 | 0 | 0 | 0 | 1 |
| [LYMC/D], G3-G2 | 0 | 0 | 0 | 0 |
| [LYMC/D], G4-G2 | 0 | 0 | 0 | 0 |
| [LYMC/D], GUnknown-G2 | 0 | 0 | 0 | 0 |
| [LYMC/D], G0-G3 | 0 | 0 | 0 | 0 |
| [LYMC/D], G1-G3 | 0 | 0 | 0 | 0 |
| [LYMC/D], G2-G3 | 0 | 0 | 0 | 0 |
| [LYMC/D], G3-G3 | 0 | 0 | 0 | 0 |
| [LYMC/D], G4-G3 | 0 | 0 | 0 | 0 |
| [LYMC/D], GUnknown-G3 | 1 | 0 | 0 | 0 |
| [LYMC/I], G0-G0 | 16 | 23 | 21 | 40 |
| [LYMC/I], G1-G0 | 0 | 0 | 0 | 0 |
| [LYMC/I], G2-G0 | 2 | 0 | 0 | 0 |
| [LYMC/I], G3-G0 | 0 | 0 | 0 | 0 |
| [LYMC/I], G4-G0 | 0 | 0 | 0 | 0 |
| [LYMC/I], GUnknown-G0 | 2 | 1 | 1 | 0 |
Laboratory abnormalities belong to hematological and biochemical parameters such as: activated partial thromboplastin time prolonged \[APTTP\], alanine aminotransferase increased \[ALT/I\], alkaline phoshatase increased \[APH/I\], anemia \[AN\], asparatate aminostransferase increased \[AST/I\], blood bilirubin increased \[BB/I\], creatinine increased \[CRE/I\], gamma glumatymtransferase increased \[GGT/I\], hemoglobin increased \[Hgb/I\], hypoalbuminemia \[HYP\], lymphocyte count decreased \[LYMC/D\], lymphocyte count increased \[LYMC/I\], neutrophil count decreased \[NEUC/D\], platelet count decreased \[PLA/D\], white blood cell decreased \[WBC/D\]. Parameter grades (G0,1,2,3,4,Uknown) were compared to each baseline parameter grades (GUnknown,0,1,2,3), as defined by the Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009 \[http://evs.nci.nih.gov/ftp1/CTCAE\]. This endpoint presents values for \[NEUC/D\], \[PLA/D\] and \[WBC/D\] grading versus baseline parameter grading.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| [NEUC/D], G0-G0 | 17 | 21 | 21 | 39 |
| [NEUC/D], G1-G0 | 1 | 2 | 0 | 0 |
| [NEUC/D], G2-G0 | 0 | 0 | 0 | 0 |
| [NEUC/D], G3-G0 | 0 | 0 | 0 | 0 |
| [NEUC/D], G4-G0 | 0 | 0 | 0 | 0 |
| [NEUC/D], GUnknown-G0 | 2 | 1 | 1 | 0 |
| [NEUC/D], G0-G1 | 0 | 0 | 0 | 0 |
| [NEUC/D], G1-G1 | 0 | 0 | 0 | 1 |
| [NEUC/D], G2-G1 | 0 | 0 | 0 | 0 |
| [NEUC/D], G3-G1 | 0 | 0 | 0 | 0 |
| [NEUC/D], G4-G1 | 0 | 0 | 0 | 0 |
| [NEUC/D], GUnknown-G1 | 0 | 0 | 0 | 0 |
| [PLA/D], G0-G0 | 17 | 24 | 20 | 38 |
| [PLA/D], G1-G0 | 1 | 0 | 0 | 2 |
| [PLA/D], G2-G0 | 0 | 0 | 0 | 0 |
| [PLA/D], G3-G0 | 0 | 0 | 0 | 0 |
| [PLA/D], G4-G0 | 0 | 0 | 0 | 0 |
| [PLA/D], GUnknown-G0 | 2 | 0 | 1 | 0 |
| [PLA/D], G0-G1 | 0 | 0 | 0 | 0 |
| [PLA/D], G1-G1 | 0 | 0 | 1 | 0 |
| [PLA/D], G2-G1 | 0 | 0 | 0 | 0 |
| [PLA/D], G3-G1 | 0 | 0 | 0 | 0 |
| [PLA/D], G4-G1 | 0 | 0 | 0 | 0 |
| [PLA/D], GUnknown-G1 | 0 | 0 | 0 | 0 |
| [WBC/D], G0-G0 | 14 | 21 | 19 | 34 |
| [WBC/D], G1-G0 | 2 | 1 | 1 | 3 |
| [WBC/D], G2-G0 | 0 | 0 | 0 | 0 |
| [WBC/D], G3-G0 | 0 | 0 | 0 | 0 |
| [WBC/D], G4-G0 | 0 | 0 | 0 | 0 |
| [WBC/D], GUnknown-G0 | 2 | 0 | 1 | 0 |
| [WBC/D], G0-G1 | 1 | 0 | 0 | 2 |
| [WBC/D], G1-G1 | 1 | 2 | 1 | 1 |
| [WBC/D], G2-G1 | 0 | 0 | 0 | 0 |
| [WBC/D], G3-G1 | 0 | 0 | 0 | 0 |
| [WBC/D], G4-G1 | 0 | 0 | 0 | 0 |
| [WBC/D], GUnknown-G1 | 0 | 0 | 0 | 0 |
Cellular response was defined as: Geometric Mean Response (GMR) above the 2.68 cut-off value and at least a four-fold increase of PRAME- specific Cluster of Differentiation (CD) 4/8 T-cells. Considering that 2 studies failed to demonstrate clinical efficacy of recombinant protein based cancer vaccines, GSK decided in 2014 to stop the development and to stop recruitment in all the ongoing clinical studies. The decision was made to end the study (i.e., stopping patient enrollment, follow-ups, sample collection and analysis of samples for research purposes). Patients still on treatment at the time of the protocol amendment were offered to continue the administration of the study treatment until the last dose or until recurrence, whichever came first, or until the patient or the investigator decided to stop the study treatment. No further active protocol visit/contact was performed except for the concluding visit at Week 199, 30 days after the last treatment administration.
| Percentage of patients | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 |
|---|---|---|---|
| Patients with CD4 pre+post-administration results | 100 (63.1 to 100) | 100 (71.5 to 100) | 100 (76.8 to 100) |
| Responders CD4 | 75.0 (34.9 to 96.8) | 45.5 (16.7 to 76.6) | 57.1 (28.9 to 82.3) |
| Patients with CD8 pre+post-administration results | 100 (63.1 to 100) | 100 (66.4 to 100) | 100 (63.1 to 100) |
| Responders CD8 | 0.0 (0.0 to 36.9) | 0.0 (0.0 to 33.6) | 0.0 (0.0 to 36.9) |
A seropositive patient was a patient whose anti-PRAME antibody concentration was greater than or equal to (≥) the assay cut-off value of 12 ELISA units per milliliter (EL.U/mL). A seronegative patient was defined as a patient whose pre-treatment antibody concentration was below (\<) the cut-off value. An anti-PRAME antibody responder was defined as: For a seronegative patient: a post-treatment antibody concentration ≥ the cut-off value; For a seropositive patient: a post-treatment antibody concentration ≥ twice the pre-treatment antibody concentration.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| anti-PRAME,Week 0 | 0 | 0 | 0 | 2 |
| anti-PRAME, Week 4 | 11 | 14 | 18 | 33 |
| anti-PRAME, Week 8 | 14 | 13 | 21 | 33 |
| anti-PRAME, Week 10 | 10 | 12 | 19 | 33 |
| anti-PRAME, Week 12 | 9 | 9 | 16 | 28 |
| anti-PRAME, Week 29 | 2 | 4 | 5 | 13 |
| anti-PRAME, Week 51 | 1 | 3 | 3 | 7 |
| anti-PRAME, Week 75 | 2 | 2 | 2 | 1 |
| anti-PRAME, Week 99 | 2 | 2 | 2 | 0 |
| anti-PRAME, Week 123 | 1 | 1 | 1 | 0 |
| anti-PRAME, Week 147 | 1 | 0 | 0 | 0 |
| anti-PRAME, Week 199 | 6 | 12 | 8 | 23 |
Tumor response was assessed by the Response Evaluation Criteria In Solid Tumors (RECIST), where stable disease for target lesions refers to neither enough shrinkage to qualify for complete response nor sufficient increase to qualify for progressive disease taking as references the smallest sum longest diameter (LD) since the treatment started. For non-targeted lesions it refers to persistence of one or more non-target lesions. Progressive disease is related to a clear increase of diameters of lesions taking as references the smallest diameters recorded since the treatment started OR the appearance of one or more new lesions OR both of these.
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| Complete response | 0 | 0 | 0 | 0 |
| Partial response | 0 | 0 | 0 | 4 |
| Stable disease | 2 | 1 | 1 | 1 |
| Stable Disease/Progressive disease | 0 | 1 | 1 | 3 |
| Progressive disease | 9 | 18 | 15 | 31 |
| Non Evaluable | 2 | 1 | 0 | 1 |
| Missing Best overall response | 7 | 3 | 5 | 0 |
| Disease control: Yes | 2 | 2 | 2 | 8 |
| Disease control: No | 18 | 22 | 20 | 32 |
Tumor response was assessed by the RECIST criteria, where SD for target lesions refers to neither enough shrinkage to qualify for CR nor sufficient increase to qualify for PD taking as references the smallest sum longest diameter (LD) since the treatment started. For non-targeted lesions it refers to persistence of one or more nom-target lesions. Progressive disease is related to a clear increase of diameters of lesions taking as references the smallest diameters recorded since the treatment started OR the appearance of one or more new lesions OR both of these. Mixed response is defined as at least 30% decrease in the LD occurring in at least one target lesion recorded and measured at baseline. Such response occurring in otherwise SD or PD status of the LD of target lesions were classified as "SD with target lesion regression" or "PD with target lesion regression", respectively. New lesion(s) in otherwise PR status of the LD of target lesions were "PR with new lesion".
| Participants | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| PR | 0 | 0 | 0 | 0 |
| CR | 0 | 0 | 0 | 4 |
| MxR: SD with target lesion regression | 0 | 0 | 0 | 0 |
| MxR: PD with target lesion regression | 2 | 2 | 2 | 3 |
| MxR: PR with new lesion | 0 | 0 | 1 | 0 |
| SD/PR | 0 | 1 | 1 | 3 |
| SD without mixed response | 2 | 0 | 1 | 1 |
| PD with SPD criteria | 3 | 5 | 4 | 19 |
| PD without SPD/MxR | 4 | 12 | 8 | 9 |
| Non Evaluable | 2 | 1 | 0 | 1 |
| Missing Best overall response | 7 | 3 | 5 | 0 |
Analysis of immunogenicity for anti-PD antibodies was not performed, following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-PD antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.
No measurements were reported for this outcome.
Analysis of immunogenicity for anti-CpG antibodies was not performed, following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-CpG antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.
No measurements were reported for this outcome.
Time to treatment failure (TTF) was defined as the time from first administration of study product until the date of the last administration of the product, irrespective of the reason for study treatment discontinuation. Progression-free survival (PFS) was defined as the time from first adminsitration of study product until the date of either disease progression or death (for whatever reason), whichever comes first. Overall survival (OS) was defined as the time from first administration of study product until death.
| Months | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| TTF | 2.3 (1.0 to 4.9) | 2.3 (1.3 to 4.2) | 3.0 (2.3 to 4.9) | 4.6 (2.7 to 5.3) |
| PFS | 2.7 (1.4 to 2.9) | 2.7 (1.0 to 2.8) | 2.8 (2.1 to 2.9) | 2.8 (2.7 to 3.3) |
| OS | 17.0 (8.1 to NA) | 11.5 (7.3 to NA) | 10.8 (8.4 to 25.5) | 23.0 (15.5 to NA) |
This analysis was not performed following negative results to the NCT00480025 study which assessed another study product from same technology platform. For this study, the main analysis of the dose-escalation Phase I segment was performed according to protocol when all patients enrolled in the Phase I segment had received the first 4 treatment doses and had completed Week 8. The main analysis of the Phase II segment was performed according to protocol when all patients had either completed the treatment until the end of Cycle 3 or had been withdrawn from the study treatment, with the exception of anti-CpG/anti-PD antibody responses and PRAME-specific cellular responses which were not yet performed. All samples that had been collected but not yet tested were not tested by default, except if a scientific rationale remained relevant.
No measurements were reported for this outcome.
Collected over Unsolicited AEs and serious adverse events (SAEs): from study start (Day 0) up to the concluding visit, at Month 49 (Week 199).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK2302025A Cohort 1 | 0/20 (0%) | 3/20 (15%) | 19/20 (95%) |
| GSK2302025A Cohort 2 | 0/24 (0%) | 3/24 (12.5%) | 21/24 (87.5%) |
| GSK2302025A Cohort 3 | 0/22 (0%) | 2/22 (9.1%) | 21/22 (95.5%) |
| GSK2302025A Cohort 4 | 2/40 (5%) | 5/40 (12.5%) | 37/40 (92.5%) |
| Event | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 1/20 | 0/24 | 0/22 | 0/40 |
| FatigueGeneral disorders | 1/20 | 0/24 | 0/22 | 0/40 |
| PainGeneral disorders | 1/20 | 0/24 | 0/22 | 0/40 |
| ErysipelasInfections and infestations | 1/20 | 0/24 | 0/22 | 0/40 |
| Infected skin ulcerInfections and infestations | 1/20 | 0/24 | 0/22 | 0/40 |
| BursitisMusculoskeletal and connective tissue disorders | 1/20 | 0/24 | 0/22 | 0/40 |
| SciaticaNervous system disorders | 1/20 | 0/24 | 0/22 | 0/40 |
| Skin ulcerSkin and subcutaneous tissue disorders | 1/20 | 0/24 | 0/22 | 0/40 |
| Intestinal obstructionGastrointestinal disorders | 0/20 | 0/24 | 1/22 | 0/40 |
| HaematuriaRenal and urinary disorders | 0/20 | 0/24 | 1/22 | 0/40 |
| Event | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 |
|---|---|---|---|---|
| Injection site painGeneral disorders | 9/20 | 10/24 | 12/22 | 24/40 |
| PyrexiaGeneral disorders | 6/20 | 8/24 | 5/22 | 22/40 |
| AstheniaGeneral disorders | 2/20 | 0/24 | 6/22 | 13/40 |
| Influenza like illnessGeneral disorders | 4/20 | 6/24 | 7/22 | 13/40 |
| Injection site erythemaGeneral disorders | 3/20 | 7/24 | 7/22 | 8/40 |
| HeadacheNervous system disorders | 6/20 | 5/24 | 4/22 | 7/40 |
| FatigueGeneral disorders | 5/20 | 7/24 | 6/22 | 7/40 |
| NauseaGastrointestinal disorders | 5/20 | 4/24 | 2/22 | 11/40 |
| Injection site reactionGeneral disorders | 5/20 | 4/24 | 2/22 | 2/40 |
| ChillsGeneral disorders | 4/20 | 1/24 | 4/22 | 8/40 |
| Age, Continuous(Years) | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 | Total |
|---|---|---|---|---|---|
| Mean | 60.3 ± 14.9 | 60.8 ± 15.5 | 59.5 ± 15.2 | 60.7 ± 18.1 | 60.4 ± 16.2 |
| Sex: Female, Male(Participants) | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 | Total |
|---|---|---|---|---|---|
| Female | 7 | 11 | 10 | 29 | 57 |
| Male | 13 | 13 | 12 | 11 | 49 |
| Race/Ethnicity, Customized(Participants) | GSK2302025A Cohort 1 | GSK2302025A Cohort 2 | GSK2302025A Cohort 3 | GSK2302025A Cohort 4 | Total |
|---|---|---|---|---|---|
| Geographic Ancestry — White - Caucasian / European Heritage | 20 | 23 | 21 | 40 | 104 |
| Geographic Ancestry — Unspecified | 0 | 1 | 1 | 0 | 2 |
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Sap, Icf, Csr
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
GlaxoSmithKline